Understanding immunity to influenza: implications for future vaccine development

Expert Rev Vaccines. 2023 Jan-Dec;22(1):871-875. doi: 10.1080/14760584.2023.2266033. Epub 2023 Oct 12.

Abstract

Introduction: Influenza virus changes its genotype through antigenic drift or shift making it difficult to develop immunity to infection or vaccination. Zoonotic influenza A virus (IAV) strains can become established in humans. Several impediments to human infection and transmission include sialic acid expression, host anti-viral factors (including interferons), and other elements that govern viral replication. Controlling influenza infection, replication, and transmission is important because IAVs cause annual epidemics and occasional pandemics. Effective seasonal influenza vaccines exist, but these vaccines do not fully protect against novel or pandemic strains.

Areas covered: With new vaccine production technology, vaccines can be produced rapidly. Universal IAV vaccines are being developed to protect against seasonal, novel, and zoonotic IAVs. These efforts are being enhanced and accelerated by a better understanding the host immune response to influenza viruses.

Expert opinion: This review discusses several implications for future influenza vaccine development. Host immune responses to influenza virus infection or vaccination can guide vaccine development as anti-influenza immunity is affected by responses influenced by the previous immune history including first and subsequent exposures to influenza virus infections and vaccinations.

Keywords: Influenza; host immunity; human; immunity; vaccines.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Humans
  • Influenza A virus* / genetics
  • Influenza Vaccines*
  • Influenza, Human*
  • Orthomyxoviridae Infections* / prevention & control
  • Orthomyxoviridae*
  • Vaccine Development

Substances

  • Influenza Vaccines